Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Global Market

2.17USD
29 Jul 2016
Change (% chg)

$0.12 (+5.85%)
Prev Close
$2.05
Open
$2.05
Day's High
$2.20
Day's Low
$2.03
Volume
42,750
Avg. Vol
28,962
52-wk High
$7.80
52-wk Low
$1.91

CYTX.OQ

Chart for CYTX.OQ

About

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused... (more)

Overall

Beta: 2.17
Market Cap(Mil.): €384.19
Shares Outstanding(Mil.): 197.76
Dividend: --
Yield (%): --

Financials

  CYTX.OQ Industry Sector
P/E (TTM): -- 42.33 39.69
EPS (TTM): -7.89 -- --
ROI: -78.90 11.52 14.44
ROE: -286.17 13.49 15.49

BRIEF-Cytori announces Maxillofacial bone regeneration trial reports

* Cytori Cell Therapy(tm) phase I trial reports Maxillofacial bone regeneration

Jul 19 2016

BRIEF-Cytori cell therapy receives limited approval in Japan

* Cytori cell therapy receives limited approval for osteoarthritis in japan

Jun 27 2016

BRIEF-Cytori completes enrollment in U.S. phase III scleroderma trial

* Cytori announces enrollment completion in U.S. Phase III scleroderma trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 07 2016

BRIEF-Cytori extends rights offering subscription period to June 10

* Extended subscription period for its previously announced rights offering until 5:00 pm et on june 10

Jun 06 2016

BRIEF-Cytori Therapeutics fully enrolls pivotal U.S. Phase III Scleroderma trial

* Cytori fully enrolls pivotal U.S. Phase III scleroderma trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 25 2016

BRIEF-Cytori Therapeutics reports Q1 loss per share $0.41 excluding items

* Cytori reports first quarter 2016 business and financial results

May 10 2016

BRIEF-Cytori granted broad European orphan drug designation

* European Commission has granted orphan drug status to a broad range of Cytori cell therapy formulations Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 10 2016

BRIEF-Cytori Therapeutics says announced additions to patent portfolio in Japan and Europe

* Says announced today a number of key additions to its patent portfolio in Japan and Europe

Apr 18 2016

BRIEF-Cytori Therapeutics files for stock offering of $11 mln

* Files for stock offering of $11 million - sec filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 06 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.